BERLIN and SEATTLE, April 18, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, yesterday presented the most recent data from its colorectal cancer screening test development program at the Annual Meeting 2007 of the American Association for Cancer Research (AACR) in Los Angeles, CA, U.S.A. The data presented showed that a modification of the assay procedure and rules for test result interpretation significantly improved the performance of Epigenomics' proprietary DNA-Methylation biomarker Septin 9 for the early detection of colorectal cancer in blood plasma.
